[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 14-year-old with genotype-positive CPVT (RYR2 mutation) who has experienced syncope with documented bidirectional VT during exercise despite being phenotype-negative previously—indicating breakthrough arrhythmia. Key discriminating findings: (1) specific RYR2 exon 3 mutation in channel core domain, (2) symptomatic bidirectional VT at 180 bpm during exercise, (3) competitive athlete context, (4) normal QTc excluding LQTS. The keyed answer (C: nadolol plus flecainide) is defensible as current guidelines recognize that beta-blocker monotherapy fails in ~30% of CPVT patients, particularly those with certain RYR2 mutations. Flecainide added to beta-blockade provides synergistic RyR2 stabilization by reducing diastolic calcium leak. Alternative analysis: (A) nadolol alone has documented failure rates and this patient already had breakthrough; (B) flecainide monotherapy without beta-blockade risks inadequate rate control; (D) verapamil is contraindicated in CPVT as it may worsen arrhythmias; (E) ICD shocks can trigger catecholamine surges causing arrhythmic storms, making ICD secondary prevention in CPVT. The item correctly reflects evolving CPVT management emphasizing combination pharmacotherapy for high-risk mutations. No logical flaws or medical inaccuracies detected. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 14-year-old with genotype-positive CPVT (RYR2 mutation) who has experienced syncope with documented bidirectional VT during exercise despite being phenotype-negative previously—indicating breakthrough arrhythmia. Key discriminating findings: (1) specific RYR2 exon 3 mutation in channel core domain, (2) symptomatic bidirectional VT at 180 bpm during exercise, (3) competitive athlete context, (4) normal QTc excluding LQTS. The keyed answer (C: nadolol plus flecainide) is defensible as current guidelines recognize that beta-blocker monotherapy fails in ~30% of CPVT patients, particularly those with certain RYR2 mutations. Flecainide added to beta-blockade provides synergistic RyR2 stabilization by reducing diastolic calcium leak. Alternative analysis: (A) nadolol alone has documented failure rates and this patient already had breakthrough; (B) flecainide monotherapy without beta-blockade risks inadequate rate control; (D) verapamil is contraindicated in CPVT as it may worsen arrhythmias; (E) ICD shocks can trigger catecholamine surges causing arrhythmic storms, making ICD secondary prevention in CPVT. The item correctly reflects evolving CPVT management emphasizing combination pharmacotherapy for high-risk mutations. No logical flaws or medical inaccuracies detected. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. Key stem clues: 72-hour-old neonate with severe hyperammonemia (920 μmol/L), undetectable urine orotic acid, elevated glutamine with decreased citrulline and arginine. These findings are classic for CPS1 deficiency (proximal urea cycle defect before orotic acid production). Main logical issue: The rationale contains a fundamental error. Carglumic acid activates CPS1 by serving as an N-acetylglutamate (NAG) analog, but it is indicated for NAG synthase deficiency, NOT CPS1 deficiency. In CPS1 deficiency, the enzyme itself is defective; providing more cofactor (NAG or its analog) cannot restore function of an absent/nonfunctional enzyme. The correct answer should be D (arginine HCl), which provides an alternative nitrogen disposal pathway by replenishing depleted urea cycle intermediates and enabling residual cycle function. Sodium phenylbutyrate (A) is also appropriate for ammonia scavenging but doesn't 'directly address the enzymatic defect' as specifically as arginine does by bypassing the block. Main medical accuracy issue: Misapplication of carglumic acid indication. Minimal fix: Change key to D or clarify that question asks for ammonia-lowering therapy rather than 'directly addressing enzymatic defect.'\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. Key stem clues: 72-hour-old neonate with severe hyperammonemia (920 μmol/L), undetectable urine orotic acid, elevated glutamine with decreased citrulline and arginine. These findings are classic for CPS1 deficiency (proximal urea cycle defect before orotic acid production). Main logical issue: The rationale contains a fundamental error. Carglumic acid activates CPS1 by serving as an N-acetylglutamate (NAG) analog, but it is indicated for NAG synthase deficiency, NOT CPS1 deficiency. In CPS1 deficiency, the enzyme itself is defective; providing more cofactor (NAG or its analog) cannot restore function of an absent/nonfunctional enzyme. The correct answer should be D (arginine HCl), which provides an alternative nitrogen disposal pathway by replenishing depleted urea cycle intermediates and enabling residual cycle function. Sodium phenylbutyrate (A) is also appropriate for ammonia scavenging but doesn't 'directly address the enzymatic defect' as specifically as arginine does by bypassing the block. Main medical accuracy issue: Misapplication of carglumic acid indication. Minimal fix: Change key to D or clarify that question asks for ammonia-lowering therapy rather than 'directly addressing enzymatic defect.'", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic Irukandji syndrome: thumbnail-sized jellyfish (Carukia barnesi) off Great Barrier Reef, delayed onset (45 min) of severe back pain, dyspnea, pulmonary edema, and hypertension (190 mmHg systolic). Key discriminating findings are the geographic location, small jellyfish size, delayed catecholamine storm presentation. The pathophysiology involves massive catecholamine release causing the hypertensive crisis and pulmonary edema. Magnesium sulfate (B) specifically antagonizes this cascade by inhibiting presynaptic catecholamine release and reducing calcium influx, making it the definitive treatment. Chironex antivenom (A) is for box jellyfish, not Irukandji species. Calcium gluconate (C) would paradoxically worsen catecholamine release. Fentanyl (D) provides only symptomatic pain relief without addressing pathophysiology. Verapamil (E) treats hypertension but doesn't antagonize the underlying catecholamine release mechanism. The question asks specifically for therapy that antagonizes the pathophysiologic cascade, which uniquely points to magnesium. Medical accuracy is high; this represents established management of Irukandji syndrome. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic Irukandji syndrome: thumbnail-sized jellyfish (Carukia barnesi) off Great Barrier Reef, delayed onset (45 min) of severe back pain, dyspnea, pulmonary edema, and hypertension (190 mmHg systolic). Key discriminating findings are the geographic location, small jellyfish size, delayed catecholamine storm presentation. The pathophysiology involves massive catecholamine release causing the hypertensive crisis and pulmonary edema. Magnesium sulfate (B) specifically antagonizes this cascade by inhibiting presynaptic catecholamine release and reducing calcium influx, making it the definitive treatment. Chironex antivenom (A) is for box jellyfish, not Irukandji species. Calcium gluconate (C) would paradoxically worsen catecholamine release. Fentanyl (D) provides only symptomatic pain relief without addressing pathophysiology. Verapamil (E) treats hypertension but doesn't antagonize the underlying catecholamine release mechanism. The question asks specifically for therapy that antagonizes the pathophysiologic cascade, which uniquely points to magnesium. Medical accuracy is high; this represents established management of Irukandji syndrome. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes DADA2 (deficiency of adenosine deaminase 2) with classic features: recurrent lacunar strokes, livedo racemosa, systemic vasculitis, necrotizing vasculitis without immune complexes, hypogammaglobulinemia (low IgM), and confirmed biallelic ADA2 mutations. Key discriminating findings establish DADA2 diagnosis unambiguously. The question asks which biologic directly interrupts the disease-driving cascade. DADA2 pathophysiology involves excess TNF-α signaling due to loss of ADA2's anti-inflammatory function. Among options, only TNF inhibitors (C and D) target the primary pathway. Adalimumab (D), a monoclonal anti-TNF antibody, is superior to etanercept (C), a soluble TNF receptor fusion protein, because etanercept can bind mutant ADA2 protein and paradoxically worsen inflammation in DADA2—a well-documented phenomenon in the literature. Prednisone (A) and cyclophosphamide (B) are non-specific immunosuppressants. Anakinra (E) targets IL-1, not the primary TNF-driven pathway. The keyed answer D is medically accurate and uniquely defensible based on DADA2-specific pathophysiology and clinical evidence showing adalimumab's superiority. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes DADA2 (deficiency of adenosine deaminase 2) with classic features: recurrent lacunar strokes, livedo racemosa, systemic vasculitis, necrotizing vasculitis without immune complexes, hypogammaglobulinemia (low IgM), and confirmed biallelic ADA2 mutations. Key discriminating findings establish DADA2 diagnosis unambiguously. The question asks which biologic directly interrupts the disease-driving cascade. DADA2 pathophysiology involves excess TNF-α signaling due to loss of ADA2's anti-inflammatory function. Among options, only TNF inhibitors (C and D) target the primary pathway. Adalimumab (D), a monoclonal anti-TNF antibody, is superior to etanercept (C), a soluble TNF receptor fusion protein, because etanercept can bind mutant ADA2 protein and paradoxically worsen inflammation in DADA2—a well-documented phenomenon in the literature. Prednisone (A) and cyclophosphamide (B) are non-specific immunosuppressants. Anakinra (E) targets IL-1, not the primary TNF-driven pathway. The keyed answer D is medically accurate and uniquely defensible based on DADA2-specific pathophysiology and clinical evidence showing adalimumab's superiority. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a classic GCK-MODY (MODY2) presentation: young adult, mild stable fasting hyperglycemia (108-115 mg/dL), HbA1c 5.7-6.4% range (6.1-6.3%), normal BMI, negative autoantibodies, autosomal dominant pattern (both parents affected), and confirmed heterozygous GCK pathogenic variant. Key discriminating findings are the stable mild hyperglycemia with confirmed genetic diagnosis. GCK-MODY causes a reset glucose setpoint (~140 mg/dL) but maintains tight glycemic regulation around this higher threshold. Longitudinal studies consistently demonstrate no increased risk of microvascular or macrovascular complications, making pharmacologic intervention unnecessary and unsupported by evidence. The keyed answer D (no pharmacologic therapy) is the established standard of care. Alternative assessments: A (Metformin) - not indicated as GCK-MODY doesn't progress and has no complication risk; B (Glipizide) - sulfonylureas are ineffective because they cannot overcome the glucokinase defect; C (Sitagliptin) - unnecessary and won't meaningfully alter the reset setpoint; E (Insulin) - completely inappropriate for this benign condition. Medical accuracy is excellent; the explanation correctly cites natural history data and mechanism. No fix needed; item is unambiguous and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic GCK-MODY (MODY2) presentation: young adult, mild stable fasting hyperglycemia (108-115 mg/dL), HbA1c 5.7-6.4% range (6.1-6.3%), normal BMI, negative autoantibodies, autosomal dominant pattern (both parents affected), and confirmed heterozygous GCK pathogenic variant. Key discriminating findings are the stable mild hyperglycemia with confirmed genetic diagnosis. GCK-MODY causes a reset glucose setpoint (~140 mg/dL) but maintains tight glycemic regulation around this higher threshold. Longitudinal studies consistently demonstrate no increased risk of microvascular or macrovascular complications, making pharmacologic intervention unnecessary and unsupported by evidence. The keyed answer D (no pharmacologic therapy) is the established standard of care. Alternative assessments: A (Metformin) - not indicated as GCK-MODY doesn't progress and has no complication risk; B (Glipizide) - sulfonylureas are ineffective because they cannot overcome the glucokinase defect; C (Sitagliptin) - unnecessary and won't meaningfully alter the reset setpoint; E (Insulin) - completely inappropriate for this benign condition. Medical accuracy is excellent; the explanation correctly cites natural history data and mechanism. No fix needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best. The vignette describes a 65-year-old man with heart failure and classic features of cardiac AL amyloidosis: increased LV wall thickness (15 mm), severely reduced global longitudinal strain (-8%), apical sparing pattern (ratio 2.5), and elevated serum lambda light chains with abnormal free light chain difference. These findings establish AL amyloidosis with cardiac involvement. The question asks for a regimen with demonstrated survival benefit in stage IIIb disease. Option B (daratumumab-bortezomib-dexamethasone) is correct based on the ANDROMEDA trial, which showed improved hematologic response rates and cardiac outcomes in AL amyloidosis patients. Option A (bortezomib-cyclophosphamide-dexamethasone) is effective but lacks the survival benefit demonstrated with daratumumab addition. Option C (heart transplant) is not standard for stage IIIb disease due to poor candidacy. Option D (doxycycline) remains investigational without proven survival benefit. Option E (tafamidis) treats ATTR amyloidosis, not AL amyloidosis. The stem provides sufficient discriminating features to identify AL amyloidosis and select the evidence-based treatment. Medical accuracy is high, consistent with current guidelines. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. The vignette describes a 65-year-old man with heart failure and classic features of cardiac AL amyloidosis: increased LV wall thickness (15 mm), severely reduced global longitudinal strain (-8%), apical sparing pattern (ratio 2.5), and elevated serum lambda light chains with abnormal free light chain difference. These findings establish AL amyloidosis with cardiac involvement. The question asks for a regimen with demonstrated survival benefit in stage IIIb disease. Option B (daratumumab-bortezomib-dexamethasone) is correct based on the ANDROMEDA trial, which showed improved hematologic response rates and cardiac outcomes in AL amyloidosis patients. Option A (bortezomib-cyclophosphamide-dexamethasone) is effective but lacks the survival benefit demonstrated with daratumumab addition. Option C (heart transplant) is not standard for stage IIIb disease due to poor candidacy. Option D (doxycycline) remains investigational without proven survival benefit. Option E (tafamidis) treats ATTR amyloidosis, not AL amyloidosis. The stem provides sufficient discriminating features to identify AL amyloidosis and select the evidence-based treatment. Medical accuracy is high, consistent with current guidelines. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best option. The stem describes a 4-day-old neonate with KCNQ2 gain-of-function mutation causing refractory neonatal epilepsy. Key discriminating findings: burst-suppression EEG, multifocal seizures, failure of phenobarbital/levetiracetam, de novo KCNQ2 gain-of-function mutation. The rationale correctly identifies that KCNQ2 gain-of-function mutations respond to sodium channel blockade. However, carbamazepine (option C, the key) is contraindicated in neonates due to serious adverse effects and lack of safety data in this age group. Phenytoin (option B) is the appropriate sodium channel blocker for neonatal use and is actually used in KCNQ2-related neonatal epilepsy. The item contains a critical medical accuracy error: while the mechanism (sodium channel blockade) is correct, the specific drug choice is age-inappropriate. Options A, D, and E are correctly eliminated as less effective for this channelopathy. The item has a unique best answer (sodium channel blockade with phenytoin, option B), but the key incorrectly points to carbamazepine. Minimal fix: Change the correct answer key from C to B, or if carbamazepine is intended, change the patient age to older infant/child where carbamazepine is appropriate.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best option. The stem describes a 4-day-old neonate with KCNQ2 gain-of-function mutation causing refractory neonatal epilepsy. Key discriminating findings: burst-suppression EEG, multifocal seizures, failure of phenobarbital/levetiracetam, de novo KCNQ2 gain-of-function mutation. The rationale correctly identifies that KCNQ2 gain-of-function mutations respond to sodium channel blockade. However, carbamazepine (option C, the key) is contraindicated in neonates due to serious adverse effects and lack of safety data in this age group. Phenytoin (option B) is the appropriate sodium channel blocker for neonatal use and is actually used in KCNQ2-related neonatal epilepsy. The item contains a critical medical accuracy error: while the mechanism (sodium channel blockade) is correct, the specific drug choice is age-inappropriate. Options A, D, and E are correctly eliminated as less effective for this channelopathy. The item has a unique best answer (sodium channel blockade with phenytoin, option B), but the key incorrectly points to carbamazepine. Minimal fix: Change the correct answer key from C to B, or if carbamazepine is intended, change the patient age to older infant/child where carbamazepine is appropriate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 36-year-old woman with migraine with aura, acute stroke (NIHSS 8, <90 minutes), and MRI showing anterior temporal lobe T2 hyperintensities with external capsule involvement—classic CADASIL features. The question asks which intervention is contraindicated due to disease-specific pathophysiology. The keyed answer (A: IV tPA) is defensible based on concerns about hemorrhagic risk in CADASIL's fragile vessels. However, option E (mechanical thrombectomy) is equally or more defensible as contraindicated: the rationale itself states thrombectomy is contraindicated for lacunar strokes typical in CADASIL, and NIHSS 8 with external capsule involvement suggests a lacunar/small-vessel stroke rather than large-vessel occlusion amenable to thrombectomy. The stem doesn't specify vessel imaging to confirm large-vessel occlusion, making both tPA and thrombectomy defensible as contraindicated. Medical accuracy issues: While CADASIL increases hemorrhagic risk, absolute contraindication of tPA is debated; some sources suggest case-by-case assessment. The claim that thrombectomy is contraindicated in CADASIL lacunar strokes is accurate but creates option overlap. Minimal fix: Specify large-vessel occlusion on imaging to make thrombectomy clearly indicated and tPA the unique contraindicated option, or clarify the specific contraindication being tested.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 36-year-old woman with migraine with aura, acute stroke (NIHSS 8, <90 minutes), and MRI showing anterior temporal lobe T2 hyperintensities with external capsule involvement—classic CADASIL features. The question asks which intervention is contraindicated due to disease-specific pathophysiology. The keyed answer (A: IV tPA) is defensible based on concerns about hemorrhagic risk in CADASIL's fragile vessels. However, option E (mechanical thrombectomy) is equally or more defensible as contraindicated: the rationale itself states thrombectomy is contraindicated for lacunar strokes typical in CADASIL, and NIHSS 8 with external capsule involvement suggests a lacunar/small-vessel stroke rather than large-vessel occlusion amenable to thrombectomy. The stem doesn't specify vessel imaging to confirm large-vessel occlusion, making both tPA and thrombectomy defensible as contraindicated. Medical accuracy issues: While CADASIL increases hemorrhagic risk, absolute contraindication of tPA is debated; some sources suggest case-by-case assessment. The claim that thrombectomy is contraindicated in CADASIL lacunar strokes is accurate but creates option overlap. Minimal fix: Specify large-vessel occlusion on imaging to make thrombectomy clearly indicated and tPA the unique contraindicated option, or clarify the specific contraindication being tested.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 29-year-old with recurrent fevers >38.5°C, severe abdominal pain, myalgia, and periorbital edema plus a TNFRSF1A cysteine mutation—classic for TRAPS (TNF Receptor-Associated Periodic Syndrome). Key discriminating findings: lifelong periodic fevers, multi-system inflammation (abdominal, musculoskeletal, periorbital), and the pathognomonic TNFRSF1A mutation. The question explicitly asks for therapy preferred over etanercept due to mechanistic considerations. Anakinra (C) is correct: TRAPS involves misfolded TNFR1 that can bind etanercept (a soluble TNF receptor fusion protein), forming complexes that paradoxically prolong inflammation rather than suppress it. IL-1 plays a central pathogenic role in TRAPS, making IL-1 blockade (anakinra, canakinumab) mechanistically superior. Anakinra is first-line per expert consensus. Canakinumab (D) also blocks IL-1 but is typically second-line and less frequently used than anakinra for TRAPS. Colchicine (A) is ineffective. Etanercept (B) is explicitly contraindicated by the question stem. Tocilizumab (E) targets IL-6, not the primary IL-1-driven pathway. No logical flaws; the stem uniquely supports anakinra. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 29-year-old with recurrent fevers >38.5°C, severe abdominal pain, myalgia, and periorbital edema plus a TNFRSF1A cysteine mutation—classic for TRAPS (TNF Receptor-Associated Periodic Syndrome). Key discriminating findings: lifelong periodic fevers, multi-system inflammation (abdominal, musculoskeletal, periorbital), and the pathognomonic TNFRSF1A mutation. The question explicitly asks for therapy preferred over etanercept due to mechanistic considerations. Anakinra (C) is correct: TRAPS involves misfolded TNFR1 that can bind etanercept (a soluble TNF receptor fusion protein), forming complexes that paradoxically prolong inflammation rather than suppress it. IL-1 plays a central pathogenic role in TRAPS, making IL-1 blockade (anakinra, canakinumab) mechanistically superior. Anakinra is first-line per expert consensus. Canakinumab (D) also blocks IL-1 but is typically second-line and less frequently used than anakinra for TRAPS. Colchicine (A) is ineffective. Etanercept (B) is explicitly contraindicated by the question stem. Tocilizumab (E) targets IL-6, not the primary IL-1-driven pathway. No logical flaws; the stem uniquely supports anakinra. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem presents a 21-year-old with hypertension, 4-cm adrenal mass, elevated normetanephrine (8.2 nmol/L), and SDHB variant, consistent with pheochromocytoma. The question asks about preoperative preparation addressing the \\\"unique catecholamine synthesis profile\\\" of SDH-related tumors. Key issue: While the rationale claims SDH-related tumors have \\\"high tyrosine hydroxylase activity\\\" requiring dual therapy (phenoxybenzamine + metyrosine), this is not standard teaching or widely accepted in major guidelines. Most endocrine surgery references and guidelines (Endocrine Society, AAES) recommend alpha-blockade (phenoxybenzamine or doxazosin) as primary preoperative preparation for pheochromocytoma, with metyrosine reserved for refractory cases, large tumors, or metastatic disease—not routinely for SDHB mutations. The stem lacks critical details (tumor size adequacy for metyrosine, symptom severity, catecholamine levels beyond normetanephrine) needed to justify dual therapy over standard alpha-blockade alone (Option A). Without explicit indication that standard alpha-blockade is insufficient, both A and C are defensible, making this underspecified. Minimal fix: Add explicit stem details indicating refractory hypertension despite alpha-blockade or extremely elevated catecholamines necessitating metyrosine, or cite specific evidence that SDHB mutations require dual therapy as standard.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem presents a 21-year-old with hypertension, 4-cm adrenal mass, elevated normetanephrine (8.2 nmol/L), and SDHB variant, consistent with pheochromocytoma. The question asks about preoperative preparation addressing the \"unique catecholamine synthesis profile\" of SDH-related tumors. Key issue: While the rationale claims SDH-related tumors have \"high tyrosine hydroxylase activity\" requiring dual therapy (phenoxybenzamine + metyrosine), this is not standard teaching or widely accepted in major guidelines. Most endocrine surgery references and guidelines (Endocrine Society, AAES) recommend alpha-blockade (phenoxybenzamine or doxazosin) as primary preoperative preparation for pheochromocytoma, with metyrosine reserved for refractory cases, large tumors, or metastatic disease—not routinely for SDHB mutations. The stem lacks critical details (tumor size adequacy for metyrosine, symptom severity, catecholamine levels beyond normetanephrine) needed to justify dual therapy over standard alpha-blockade alone (Option A). Without explicit indication that standard alpha-blockade is insufficient, both A and C are defensible, making this underspecified. Minimal fix: Add explicit stem details indicating refractory hypertension despite alpha-blockade or extremely elevated catecholamines necessitating metyrosine, or cite specific evidence that SDHB mutations require dual therapy as standard.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}]